Literature DB >> 24315915

Effects of heparin on temporal microRNA profiles.

Manuel Mayr, Regent Lee, Dorothee Kaudewitz, Anna Zampetaki, Keith M Channon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24315915      PMCID： PMC5357045          DOI： 10.1016/j.jacc.2013.07.118

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  8 in total

1.  Analytical challenges and technical limitations in assessing circulating miRNAs.

Authors:  Anna Zampetaki; Manuel Mayr
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

2.  MicroRNA and myocardial infarction: a mystery turning into glory?

Authors:  Luigi M Biasucci; Maria Teresa Cardillo
Journal:  J Am Coll Cardiol       Date:  2013-06-07       Impact factor: 24.094

3.  Release kinetics of circulating muscle-enriched microRNAs in patients undergoing transcoronary ablation of septal hypertrophy.

Authors:  Christoph Liebetrau; Helge Möllmann; Oliver Dörr; Sebastian Szardien; Christian Troidl; Matthias Willmer; Sandra Voss; Luise Gaede; Johannes Rixe; Andreas Rolf; Christian Hamm; Holger Nef
Journal:  J Am Coll Cardiol       Date:  2013-06-07       Impact factor: 24.094

4.  Prospective study on circulating MicroRNAs and risk of myocardial infarction.

Authors:  Anna Zampetaki; Peter Willeit; Lindsey Tilling; Ignat Drozdov; Marianna Prokopi; Jean-Marie Renard; Agnes Mayr; Siegfried Weger; Georg Schett; Ajay Shah; Chantal M Boulanger; Johann Willeit; Philip J Chowienczyk; Stefan Kiechl; Manuel Mayr
Journal:  J Am Coll Cardiol       Date:  2012-07-24       Impact factor: 24.094

5.  Circulating microRNAs as novel biomarkers for platelet activation.

Authors:  Peter Willeit; Anna Zampetaki; Katarzyna Dudek; Dorothee Kaudewitz; Alice King; Nicholas S Kirkby; Roxanne Crosby-Nwaobi; Marianna Prokopi; Ignat Drozdov; Sarah R Langley; Sobha Sivaprasad; Hugh S Markus; Jane A Mitchell; Timothy D Warner; Stefan Kiechl; Manuel Mayr
Journal:  Circ Res       Date:  2013-01-02       Impact factor: 17.367

6.  Heparin selectively affects the quantification of microRNAs in human blood samples.

Authors:  Jes-Niels Boeckel; Claudia E Thomé; David Leistner; Andreas M Zeiher; Stephan Fichtlscherer; Stefanie Dimmeler
Journal:  Clin Chem       Date:  2013-04-23       Impact factor: 8.327

7.  Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation.

Authors:  Michael A Fifer; Ulrich Sigwart
Journal:  Eur Heart J       Date:  2011-03-29       Impact factor: 29.983

8.  Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease.

Authors:  Dorothee Kaudewitz; Regent Lee; Peter Willeit; Reuben McGregor; Hugh S Markus; Stefan Kiechl; Anna Zampetaki; Robert F Storey; Keith M Channon; Manuel Mayr
Journal:  Thromb Haemost       Date:  2013-06-27       Impact factor: 5.249
  8 in total
  9 in total

Review 1.  A critical approach for successful use of circulating microRNAs as biomarkers in cardiovascular diseases: the case of hypertrophic cardiomyopathy.

Authors:  Dimitrios Ntelios; Elisavet Georgiou; Sofia Alexouda; Antigoni Malousi; Georgios Efthimiadis; Georgios Tzimagiorgis
Journal:  Heart Fail Rev       Date:  2021-03-03       Impact factor: 4.214

2.  Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease.

Authors:  Chi-Sheng Wu; Fen-Chiung Lin; Shu-Jen Chen; Yung-Lung Chen; Wen-Jung Chung; Cheng-I Cheng
Journal:  Biomed Res Int       Date:  2016-09-20       Impact factor: 3.411

3.  Optimisation of laboratory methods for whole transcriptomic RNA analyses in human left ventricular biopsies and blood samples of clinical relevance.

Authors:  Kerrie L Ford; Maryam Anwar; Rachael Heys; Eltayeb Mohamed Ahmed; Massimo Caputo; Laurence Game; Barnaby C Reeves; Prakash P Punjabi; Gianni D Angelini; Enrico Petretto; Costanza Emanueli
Journal:  PLoS One       Date:  2019-03-14       Impact factor: 3.240

4.  Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury.

Authors:  Christian Schulte; Temo Barwari; Abhishek Joshi; Konstantinos Theofilatos; Anna Zampetaki; Javier Barallobre-Barreiro; Bhawana Singh; Nils A Sörensen; Johannes T Neumann; Tanja Zeller; Dirk Westermann; Stefan Blankenberg; Michael Marber; Christoph Liebetrau; Manuel Mayr
Journal:  Circ Res       Date:  2019-06-04       Impact factor: 17.367

5.  MiR-223 levels predicting perioperative bleeding in off-pump coronary artery bypass grafting.

Authors:  Zi Wang; Limin Xia; Qing Xu; Qiuyi Ji; Zhifeng Yao; Qianzhou Lv
Journal:  Ann Transl Med       Date:  2020-11

6.  MicroRNAs as clinical biomarkers?

Authors:  Timothy G Angelini; Costanza Emanueli
Journal:  Front Genet       Date:  2015-07-14       Impact factor: 4.599

7.  Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device.

Authors:  Andrew C Morley-Smith; Adam Mills; Steven Jacobs; Bart Meyns; Filip Rega; André R Simon; John R Pepper; Alexander R Lyon; Thomas Thum
Journal:  Eur J Heart Fail       Date:  2014-06-24       Impact factor: 15.534

Review 8.  MicroRNA Biomarkers for Coronary Artery Disease?

Authors:  Dorothee Kaudewitz; Anna Zampetaki; Manuel Mayr
Journal:  Curr Atheroscler Rep       Date:  2015-12       Impact factor: 5.113

9.  Heparinase treatment of heparin-contaminated plasma from coronary artery bypass grafting patients enables reliable quantification of microRNAs.

Authors:  Kirill Kondratov; Dmitry Kurapeev; Maxim Popov; Marina Sidorova; Sarkis Minasian; Michael Galagudza; Anna Kostareva; Anton Fedorov
Journal:  Biomol Detect Quantif       Date:  2016-04-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.